Breaking News

Financial Report: Allergan

May 7, 2014

Specialty pharma sales up 10% in the quarter

1Q Revenues: $1.6 billion (+13%)

1Q Earnings: $257.9 million (earnings were $14.4 million in 1Q13)

Comments: Specialty pharmaceuticals sales increased 10% to $1.4 billion, with Eye Care Pharmaceutical sales of $730.4 million, up 9%, and Botox/Neuromodulators sales up 10% to $501.8 million. Medical devices sales increased 29% to $259.8 million. Earnings in 1Q13 include $258.6 million from discontinued operations associated with the sale of the obesity intervention business unit. On April 22, Allergan received an unsolicited proposal from Valeant Pharmaceuticals to acquire all outstanding shares of Allergan for approximately $47 billion. The Allergan board is currently reviewing the proposal.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks